Crestor RAPID (The Efficacy of RosuvAstatin for Korean Dyslipidemia PatIents With Diabetes)
Completed
- Conditions
- DyslipidemiaDiabetes
- Registration Number
- NCT00526552
- Lead Sponsor
- AstraZeneca
- Brief Summary
To evaluate the efficacy of rosuvastatin in Korean dyslipidemia patients with diabetes
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5000
Inclusion Criteria
-
Hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on clinical grounds and fulfil the following criteria
- Over 18 years of age
- Diagnosed with DM based on fasting or post-load glucose data and/or clinical assessment by the clinician
Exclusion Criteria
- Patients already taking other hyperlipidemic agents
- Patients who do not fulfil the indication criteria for statin therapy
- Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms by which rosuvastatin modulates lipid metabolism in Korean patients with type 2 diabetes mellitus?
How does rosuvastatin's efficacy in Korean diabetic dyslipidemia patients compare to other statin classes like atorvastatin or pravastatin?
Which specific biomarkers (e.g., HbA1c, LDL-C, CRP) were most predictive of rosuvastatin treatment outcomes in the RAPID observational study?
What adverse event profiles have been observed with rosuvastatin in Asian populations with comorbid diabetes and dyslipidemia?
How do rosuvastatin's pleiotropic effects on endothelial function and inflammation impact cardiovascular risk reduction in Korean type 2 diabetes patients with metabolic syndrome?
Trial Locations
- Locations (1)
Research Site
🇰🇷Seoul, Songpa-gu, Korea, Republic of
Research Site🇰🇷Seoul, Songpa-gu, Korea, Republic of